A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.
Phase II Clinical Study of Adebrelimab Combined with Apatinib and Paclitaxel for Injection(Albumin Bound) as Second-line Therapy in Patients with Advanced Gastric Cancer Previously Treated with Immunotherapy
Gastric Cancer
DRUG: Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)
ORR, The proportion of patients with a confirmed complete response or partial response, up to 3 years
PFS, The time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first, up to 3 years|DCR, The proportion of patients with a best overall response of confirmed complete or partial response, or stable disease, up to 3 years|OS, The time from randomization to death from any reason, up to 3 years
To observe and evaluate the efficacy of Adebrelimab combined with Apatinib and Paclitaxel for Injection(Albumin Bound) in second-line treatment of advanced gastric cancer.